Final Analysis of the Phase III PEONY Trial: Long-Term Efficacy and Safety of Neoadjuvant-Adjuvant Pertuzumab or Placebo, Plus Trastuzumab and Docetaxel, in Patients with HER2-positive Early or Locally Advanced Breast Cancer